FDA NMN dietary supplement status: what the 2025 decision means
Is NMN legal in the United States? Yes. Since 29 September 2025, the US Food and Drug Administration (FDA) says that NMN is not excluded from the definition of a dietary supplement, so it may again be sold as one. That is not an approval: the FDA does not approve dietary supplements, and NMN counts as a new dietary ingredient, so the usual notification rules apply.
Why did the FDA take NMN off the supplement list in 2022, what made it change its position, and what still applies today? In this article you read the full timeline, based on the FDA’s own letters. Updated November 2026.
NMN (nicotinamide mononucleotide) is a molecule that the body uses to make the coenzyme NAD+.

In one minute
- Since 29 September 2025, NMN is no longer excluded from the definition of a dietary supplement in the US.
- This is not an FDA approval. The FDA does not approve supplements, and NMN is a new dietary ingredient, so companies have to follow the notification rules.
- In 2022, the FDA had excluded NMN because it had been studied as a drug. In 2025, it changed its reading of the law, so the fact that NMN was sold as a supplement first now counts.
- The change followed a citizen petition and a lawsuit by the Natural Products Association (NPA).
- The decision is about legal status. It says nothing about what NMN does in the body.
Why did FDA ban NMN in the first place?
Strictly speaking, the FDA did not ban NMN. In October and November 2022, it told the companies that had notified it about NMN, including SyncoZymes and Kingdomway, that NMN is excluded from the definition of a dietary supplement. For SyncoZymes, this replaced an earlier FDA response from May 2022 that had accepted its notification without objection.
The reason was the drug exclusion clause in US law. An ingredient that has been approved as a drug, or authorised for investigation as a new drug with substantial clinical studies started and made public, cannot be sold as a dietary supplement. The main exception: the clause does not apply if the ingredient was sold as a dietary supplement or food before that approval or authorisation.
In 2022, the FDA held that NMN had not been lawfully sold as a supplement before it was authorised for investigation as a drug. Earlier sales did not count, in the FDA’s view, because no company had notified it about NMN as a new dietary ingredient before selling it. In early 2023, Amazon removed NMN supplements from its store. The supplement industry disputed the FDA’s position, because NMN had been sold as a supplement in the US for years.
The role of the NPA and the petition
In March 2023, the Natural Products Association (NPA), a US trade association for the supplement industry, and the Alliance for Natural Health USA filed a citizen petition. They asked the FDA to conclude that NMN is not excluded from the definition of a dietary supplement. In August 2024, the NPA also took the FDA to federal court.
On 29 September 2025, the FDA answered the petition and partly granted it. After that response, the NPA withdrew its lawsuit in October 2025. On the day of the decision, NPA president Daniel Fabricant said:
“FDA’s decision today confirms NMN is lawful in supplements, and we now call on e-commerce platforms to immediately restore NMN products to the market.”
Is NMN FDA approved? What the 2025 decision says
No. In the US, dietary supplements do not need FDA approval before they are sold. What changed on 29 September 2025 is the FDA’s position on the drug exclusion clause. In its letter, the FDA writes that it now concludes “that NMN is not excluded from the definition of dietary supplement”.
The reason: the FDA changed its reading of the law. Sales before a drug investigation now count even if they were not lawful, for example because no notification had been filed. NMN was on the US market as a dietary supplement as early as 2017, before it was authorised for investigation as a drug, so the exception in the drug exclusion clause applies.
The same letter also states that NMN is a new dietary ingredient. That is an ingredient that was not sold as a dietary ingredient in the US before 15 October 1994. In general, a company must notify the FDA at least 75 days before it sells a supplement with a new dietary ingredient, and include the evidence on which it bases its conclusion that the product is reasonably expected to be safe.
The FDA did not agree with the petition on every point. It rejected the argument that NMN needs no notification at all, and it kept its general reading of the drug exclusion clause for other ingredients.
On 2 December 2025, the FDA sent new letters to SyncoZymes, Kingdomway and other companies that had notified it about NMN, setting aside its 2022 letters. In the letter to SyncoZymes, it reinstated its response from May 2022, which had accepted the company’s NMN notification without objection.
| Date | What happened |
|---|---|
| 2017 | NMN is sold as a dietary supplement in the US (the earliest date the FDA mentions in its 2025 letter). |
| May 2022 | The FDA acknowledges a new dietary ingredient notification for NMN from the company SyncoZymes without objection. |
| October–November 2022 | The FDA tells the companies that had notified it about NMN, including SyncoZymes and Kingdomway, that NMN is excluded from the definition of a dietary supplement. |
| Early 2023 | Amazon removes NMN supplements from its store. |
| March 2023 | The Natural Products Association (NPA) and the Alliance for Natural Health USA file a citizen petition asking the FDA to change its position. |
| August 2024 | The NPA takes the FDA to federal court over NMN. |
| 29 September 2025 | The FDA concludes that NMN is not excluded from the definition of a dietary supplement. |
| October 2025 | The NPA withdraws its lawsuit. |
| 2 December 2025 | The FDA sends new letters to SyncoZymes, Kingdomway and other companies that had notified it about NMN, setting aside its 2022 letters. |
Find what fits you
Answer a few short questions and discover which supplements match your goals and daily routine.
Find your supplementIs NMN legal in the US now?
Yes. Since September 2025, NMN may be sold as a dietary supplement in the US. The same rules apply as for other supplements: companies are responsible for the safety of their products, must manufacture them under good manufacturing practice, may not claim that a supplement treats or prevents a disease, and must notify the FDA before they sell a new dietary ingredient, unless an exemption applies.
An FDA response to a notification without objection is a procedural step. It is not an approval and not a safety finding by the FDA.
What this means for consumers and longevity research
The FDA’s decision is about legal status, not about whether NMN has effects in people. The FDA did not assess any health effect of NMN.
Researchers study NMN because the body uses it to make NAD+, a coenzyme that plays a role in energy production in cells and that declines with age in animal and some human studies. Human trials with NMN are so far mostly small and short, and many measured NAD+ levels in the blood rather than health outcomes.
Purovitalis and the NPA
Purovitalis is a member of the Natural Products Association. We follow regulatory developments like this one closely and explain what they mean for our customers. Our CEO, Koen Ridder, said about the decision:
“We are very pleased with the FDA’s decision to restore NMN’s supplement status. This means we can continue to offer NMN to our customers. At Purovitalis, our mission has always been to bring longevity supplements based on research to consumers, and this ruling allows us to do just that.”
FDA NMN dietary supplement status in brief
Since 29 September 2025, NMN is no longer excluded from the definition of a dietary supplement in the US. It is not FDA approved, because the FDA does not approve supplements, and it counts as a new dietary ingredient, so the notification rules apply.
The decision changed the legal status of NMN in the US. Whether NMN has health effects in people is a separate question that research is still working on.
Frequently asked questions
No. The FDA does not approve dietary supplements before they are sold. Since 29 September 2025, its position is that NMN is not excluded from the definition of a dietary supplement, so NMN may again be sold as one in the US.
Yes, as an ingredient of dietary supplements. NMN counts as a new dietary ingredient, so the notification rules for new dietary ingredients and the general rules for dietary supplements apply.
In 2022, the FDA held that NMN had not been lawfully sold as a supplement before it was authorised for investigation as a drug. Under US law, that excludes an ingredient from supplements. In 2025, the FDA changed its reading of the law: earlier sales also count if they were not lawful, and NMN was on the US market as early as 2017.
An ingredient that was not sold in the US as a dietary ingredient before 15 October 1994. In general, a company must notify the FDA at least 75 days before it sells a supplement with a new dietary ingredient, and include the evidence on which it bases its conclusion that the product is reasonably expected to be safe.
NMN (nicotinamide mononucleotide) is a molecule that the body uses to make the coenzyme NAD+. Small amounts occur naturally in some foods, and it is also sold as a dietary supplement.
References
- US Food and Drug Administration. Response to citizen petition on nicotinamide mononucleotide (NMN), docket FDA-2023-P-0872, document FDA-2023-P-0872-2754. 29 September 2025. https://www.regulations.gov/document/FDA-2023-P-0872-2754
- Natural Products Association. Amid pressure from NPA, FDA declares NMN lawful in dietary supplements. 29 September 2025. https://www.npanational.org/news/amid-pressure-from-npa-fda-declares-nmn-lawful-in-dietary-supplements/
- Natural Products Association. FDA reinstates NMN as dietary supplement after NPA lawsuit. 10 December 2025. https://www.npanational.org/news/fda-reinstates-nmn-as-dietary-supplement-after-npa-lawsuit/
- US Food and Drug Administration. New dietary ingredient notification process. https://www.fda.gov/food/dietary-supplements/new-dietary-ingredient-ndi-notification-process
Add Purovitalis as a preferred source on Google Google then shows more of our articles in your search results.